Mefloquine and atovaquone-proguanil are both malaria-prevention options, but they fit very different kinds of travelers. The real decision is usually less about convenience alone and more about side-effect profile, contraindications, trip length, and what the traveler is realistically likely to tolerate.
This guide explains how clinicians think about mefloquine versus atovaquone-proguanil for travel, and why one option can be reasonable for one traveler and a poor fit for another. If you want a route-specific recommendation, you can start a Runway Health consultation online.
Why this comparison is mostly about suitability
The CDC Yellow Book malaria guidance includes both medicines among accepted prophylaxis options, but the tradeoffs differ. Atovaquone-proguanil is taken daily and usually has a shorter post-travel course, while mefloquine is weekly but has a more restrictive neuropsychiatric side-effect profile.
How clinicians think about atovaquone-proguanil
Where it often fits well
Atovaquone-proguanil is often attractive for shorter trips because it starts 1 to 2 days before travel and continues for only 7 days after leaving the malaria-risk area. Many travelers also like that it avoids the mefloquine-specific mental health cautions.
What still needs review
Daily dosing, cost, renal considerations, and traveler preference still matter. Even well-tolerated options are not automatically the right choice for every itinerary.
How clinicians think about mefloquine
Where mefloquine can still fit
Mefloquine can appeal to travelers who strongly prefer weekly dosing, especially on longer trips. In the right patient, that weekly schedule may be easier to maintain than a daily pill.
Its biggest limitation
CDC highlights that mefloquine should be avoided in travelers with certain psychiatric conditions, seizure disorders, or other contraindications. That safety screen matters more than convenience.
Start Your Travel Consultation ➜
Questions that shape the recommendation
- How long is the trip?
- Do you want weekly dosing strongly enough for it to change adherence?
- Do you have any mental-health or neurologic history that affects suitability?
- How important is a shorter post-travel medication tail?
- Do you need a broader malaria-risk review by exact route?
Related comparisons worth reviewing
This is not the same decision as Malarone versus doxycycline or Malarone versus tafenoquine. If you want to compare other prophylaxis pathways, see our Malarone vs mefloquine comparison and our Malarone vs tafenoquine guide.
The bottom line
Atovaquone-proguanil often fits travelers who want a daily option with a shorter post-travel course, while mefloquine may fit some travelers who can safely use it and prefer weekly dosing. The right answer depends on contraindications, side-effect tolerance, and clinician judgment.
Prescribing decisions are always clinician discretion and should be individualized to the traveler.
Compare Malaria Prevention Options Online ➜
